PCM
TEVA icon

Polaris Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Polaris Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,620,978
Closed -$24.2M – 84
2019
Q2 		$24.2M Sell
2,620,978
-7,590,602
-74% -$91.5M 1.02% 30
2019
Q1 		$160M Sell
10,211,580
-131,400
-1% -$2.32M 6.66% 5
2018
Q4 		$159M Buy
10,342,980
+431,942
+4% +$8.86M 7.31% 5
2018
Q3 		$213M Buy
9,911,038
+817,964
+9% +$19M 9.3% 1
2018
Q2 		$221M Sell
9,093,074
-731,200
-7% -$14.9M 10.23% 1
2018
Q1 		$168M Buy
9,824,274
+897,368
+10% +$17.5M 6.19% 4
2017
Q4 		$169M Buy
8,926,906
+4,939,569
+124% +$74.3M 7.91% 2
2017
Q3 		$70.2M Buy
3,987,337
+560,200
+16% +$12.6M 3.92% 5
2017
Q2 		$114M Buy
3,427,137
+1,326,990
+63% +$41.1M 6.7% 5
2017
Q1 		$67.4M Buy
2,100,147
+135,400
+7% +$4.62M 4.79% 4
2016
Q4 		$71.2M Buy
1,964,747
+171,400
+10% +$6.84M 4.6% 5
2016
Q3 		$82.5M Sell
1,793,347
-34,337
-2% -$1.79M 6.42% 5
2016
Q2 		$91.8M Buy
1,827,684
+53,600
+3% +$2.85M 7.98% 4
2016
Q1 		$96.6M Sell
1,774,084
-27,075
-2% -$1.59M 8.3% 3
2015
Q4 		$118M Buy
1,801,159
+89,828
+5% +$5.55M 11.97% 1
2015
Q3 		$96.6M Buy
1,711,331
+31,400
+2% +$2.04M 11.7% 2
2015
Q2 		$99.3M Buy
1,679,931
+34,200
+2% +$2.11M 12.18% 1
2015
Q1 		$103M Sell
1,645,731
-130,200
-7% -$7.57M 14.32% 1
2014
Q4 		$102M Buy
+1,775,931
New +$98.9M 17.12% 1

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Polaris Capital Management's TEVA Position: Q3 2019 in Review

Polaris Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 2,620,978 shares — an estimated $24.2M sold.

Polaris Capital Management first reported a position in TEVA in Q4 2014 and held it in 19 quarters. The position peaked at $221M in Q2 2018. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Polaris Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Polaris Capital Management sold 2,620,978 Teva Pharmaceuticals shares in Q3 2019, an estimated $24.2M.
  • Polaris Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 19 quarters.
  • Polaris Capital Management's Teva Pharmaceuticals position peaked at $221M in Q2 2018.
  • 427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Polaris Capital Management's 13F filing for Q3 2019, filed 15 Nov 2019.